Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22 févr. 2024 16h05 HE
|
Athira Pharma, Inc.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
08 févr. 2024 16h02 HE
|
Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
08 janv. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
03 janv. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12 déc. 2023 07h00 HE
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
29 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
28 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
15 nov. 2023 08h15 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
09 nov. 2023 16h05 HE
|
Athira Pharma, Inc.
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments...
Athira Pharma to Participate in Jefferies London Healthcare Conference
08 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...